Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
AUSTIN, Texas, May 13, 2021 (GLOBE NEWSWIRE) Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be presenting at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 and will be hosting virtual one-on-one meetings with investors throughout the day.
Live Presentation 10:45 AM – 11:25 AM (ET)
The live Lumos Pharma presentation can be accessed through the link Oppenheimer Rare & Orphan Disease Summit (wsw.com). The link can also be found on the Company’s website under “Events & Presentations” in the Investors & Media section where a replay will be available for 90 days. Please contact your Oppenheimer salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team during the Summit or thereafter.
Print
Singular Genomics, a San Diego startup that’s developing next-generation sequencing technology for oncology and immunology, has filed a prospectus to become a publicly traded company.
Founded in 2016, Singular hasn’t disclosed yet how much money it hopes to raise or the proposed price range of its shares. That information should be revealed as Singular gets closer to pricing its initial public stock offering.
But it is attempting an IPO at a time when investors are receptive to betting on early stage companies. There have been 141 IPOs priced globally so far this year, up more than 300 percent from the same period last year, according to Renaissance Capital, an IPO investment advisory firm. San Diego-based TuSimple, which is developing self-driving semi-truck technology, recently raised $1 billion in an IPO.
Cambridge cancer drug startup Nuvalent raises $135 million
The new funding comes just four months after it was launched with $50 million.
By Jonathan Saltzman Globe Staff,Updated May 11, 2021, 6:00 a.m.
Email to a Friend
James Porter is CEO of Cambridge biotech Nuvalent.Nuvalent
Nuvalent, a Cambridge biotech working on precision cancer drugs, has raised another $135 million in venture capital just four months after the firm was launched with $50 million in financing.
The startup is developing lung cancer drugs that rely on enzyme blockers known as kinase inhibitors to help keep cancer cells from growing. Nuvalent hopes to use cash from the second round of financing to advance two potential drugs into clinical trials.
May 11, 2021 7:00am Nuvalent will use the money to fund clinical development of its parallel lead programs, NVL-520 and NVL-655. (Robina Weermeijer/Unsplash)
Nuvalent has raised $135 million to take ROS1 and ALK kinase inhibitors into the clinic. The series B, which comes months after Nuvalent disclosed a $50 million round, sets Nuvalent up to study drugs designed to improve on products such as Roche’s Alecensa and Pfizer’s Xalkori.
Kinase inhibitors have improved cancer outcomes by binding to enzymes that drive the proliferation, survival and metastasis of tumors. However, changes to the binding sites lead to resistance, creating a need for treatments that are effective in patients who stop responding to existing drugs. Nuvalent is working to deliver those treatments.
socaltech.com
La Jolla-based
Singular Genomics Systems, a developer of gene sequencing technology, has filed for an IPO, saying in a filing that it is looking to raise up to $100M in an IPO on the Nasdaq. The company has filed to list under the symbol OMIC. The IPO is being underwritten by J.P. Morgan, Goldman Sachs & Co. LLC, BofA Securities, Cowen, and UBS Investment Bank. The company s largest shareholders are Deerfield Management, Domain Associates, Legend Capital, and Arch Venture Partners.